Abstract
AbstractMesenchymal stem cell (MSC)-based therapy has been considered as a promising approach targeting a variety of intractable diseases due to remarkable multiple effect of MSCs, such as multilineage differentiation, immunomodulatory property, and pro-regenerative capacity. However, poor engraftment, low survival rate of transplanted MSC, and impaired donor-MSC potency under host age/disease result in unsatisfactory therapeutic outcomes. Enhancement strategies, including genetic manipulation, pre-activation, and modification of culture method, have been investigated to generate highly functional MSC, and approaches for MSC pre-activation are highlighted. In this review, we summarized the current approaches of MSC pre-activation and further classified, analysed the scientific principles and main characteristics of these manipulations, and described the pros and cons of individual pre-activation strategies. We also discuss the specialized tactics to solve the challenges in this promising field so that it improves MSC therapeutic functions to serve patients better.
Funder
the National Nature Science Foundation of China
the National Key Research and Development Plan
the CAMS Innovation Fund for Medical Sciences
the Military Medical Research and Development Projects
The National S&T Resource Sharing service platform Project of China
the General Hospital of PLA Medical Big Data R&D Project
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Medicine,Medicine (miscellaneous)
Reference229 articles.
1. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12:CD007888.
2. Radrizzani M, Lo Cicero V, Soncin S, Bolis S, Surder D, Torre T, Siclari F, Moccetti T, Vassalli G, Turchetto L. Bone marrow-derived cells for cardiovascular cell therapy: an optimized GMP method based on low-density gradient improves cell purity and function. J Transl Med. 2014;12:276.
3. Seo Y, Shin TH, Kim HS. Current strategies to enhance adipose stem cell function: an update. Int J Mol Sci. 2019;20(15):3827.
4. Soria-Juan B, Escacena N, Capilla-Gonzalez V, Aguilera Y, Llanos L, Tejedo JR, Bedoya FJ, JuanV, De la Cuesta A, Ruiz-Salmeron R, Andreu E, Grochowicz L, Prosper F, Sanchez-Guijo F, Lozano FS, Miralles M, Del Rio-Sola L, Castellanos G, Moraleda JM, Sackstein R, Garcia-Arranz M, Garcia-Olmo D, Martin F, Hmadcha A, Soria B, Collaborative Working Group "Noma Project T. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus. Front Immunol. 2019;10:1151.
5. Yasuhara T, Kameda M, Sasaki T, Tajiri N, Date I. Cell therapy for Parkinson’s disease. Cell Transplant. 2017;26(9):1551–9.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献